Transthyretin Amyloidosis

PALO ALTO, Calif., August 30, 2026 BridgeBio Pharma, Inc. presented new data from the Phase 3 ATTRibute-CM study of...

Cambridge, Mass. – August 30, 2026 Alnylam Pharmaceuticals announced new clinical data at the European Society of Cardiology (ESC)...

PALO ALTO, Calif., Aug. 26, 2026 BridgeBio Pharma, Inc. has announced that the first participant has been dosed in...

NEW YORK, July 22, 2026 Royalty Pharma plc has announced the acquisition of a portion of Neurimmune’s royalty interest...